|Articles|November 20, 2020
Full Characterization in Early Method Development
Author(s)SGS
This whitepaper will look at how integrating the SEC-MALS method at an earlier stage in the development process will accelerate speed-to-clinic without compromising patient safety.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
2
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
3
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
4
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
5
